Vincent Vezza

Vincent Vezza

Auto-generated profile, based on publicly available information

Vincent Vezza

MicroplateDx

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Analytical Chemistry
Verified
Journal Article
Open access
PLPerrine Lasserre
Perrine Lasserre
BBBanushan Balansethupathy
Banushan Balansethupathy
VVVincent J. Vezza
Vincent J. Vezza
ABAdrian Butterworth
Adrian Butterworth
AMAlexander Macdonald
Alexander Macdonald
Damion CorriganDamion Corrigan
Damion Corrigan
SARS-CoV-2 diagnostic practices broadly involve either quantitative polymerase chain reaction (qPCR)-based nucleic amplification of viral sequences or antigen-based tests such as lateral flow assays (LFAs). Reverse transcriptase-qPCR can detect viral RNA and is the gold standard for sensitivity. However, the technique is time-consuming and requires expensive laboratory infrastructure and trained staff. LFAs are lower in cost and near real time, and because they are antigen-based, they have the potential to provide a more accurate indication of a disease state. However, LFAs are reported to have low real-world sensitivity and in most cases are only qualitative. Here, an antigen-based electrochemical aptamer sensor is presented, which has the potential to address some of these shortfalls. An aptamer, raised to the SARS-CoV-2 spike protein, was immobilized on a low-cost gold-coated polyester substrate adapted from the blood glucose testing industry. Clinically relevant detection levels for SARS-CoV-2 are achieved in a simple, label-free measurement format using sample incubation times as short as 15 min on nasopharyngeal swab samples. This assay can readily be optimized for mass manufacture and is compatible with a low-cost meter.

12 March 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
VVVincent J. Vezza
Vincent J. Vezza
ABAdrian Butterworth
Adrian Butterworth
PLPerrine Lasserre
Perrine Lasserre
EBEwen Blair
Ewen Blair
AMAlexander MacDonald
Alexander MacDonald
Damion CorriganDamion Corrigan
Damion Corrigan
A rapid, low cost sensor for Covid-19 was developed using a perfluorodecanthiol layer and ACE2.

6 December 2019 in Biosensors
Verified
Journal Article
Open access
PDF file
LCLisa Crossley
Lisa Crossley
BABukola Attoye
Bukola Attoye
VVVincent Vezza
Vincent Vezza
EBEwen Blair
Ewen Blair
Damion CorriganDamion Corrigan
Damion Corrigan
SHStuart Hannah
Stuart Hannah
We present a low-cost, sensitive and specific DNA field-effect transistor sensor for the rapid detection of a common mutation to the tumour protein 53 gene (TP53). The sensor consists of a commercially available, low-cost, field-effect transistor attached in series to a gold electrode sensing pad for DNA hybridisation. The sensor has been predominantly optimised electrochemically, particularly with respect to open-circuit potentiometry as a route towards understanding potential (voltage) changes upon DNA hybridisation using a transistor. The developed sensor responds sensitively to TP53 mutant DNA as low as 100 nM concentration. The sensor responds linearly as a function of DNA target concentration and is able to differentiate between complementary and noncomplementary DNA target sequences.

9 June 2018 in Sensors
Verified
Journal Article
Open access
PDF file
Damion CorriganDamion Corrigan
Damion Corrigan
VVVincent Vezza
Vincent Vezza
Holger SchulzeHolger Schulze
Holger Schulze
TBTill Bachmann
Till Bachmann
AMAndrew R. Mount
Andrew R. Mount
JTJonathan Terry
Jonathan Terry
For analytical applications involving label-free biosensors and multiple measurements, i.e., across an electrode array, it is essential to develop complete sensor systems capable of functionalization and of producing highly consistent responses. To achieve this, a multi-microelectrode device bearing twenty-four equivalent 50 µm diameter Pt disc microelectrodes was designed in an integrated 3-electrode system configuration and then fabricated. Cyclic voltammetry and electrochemical impedance spectroscopy were used for initial electrochemical characterization of the individual working electrodes. These confirmed the expected consistency of performance with a high degree of measurement reproducibility for each microelectrode across the array. With the aim of assessing the potential for production of an enhanced multi-electrode sensor for biomedical use, the working electrodes were then functionalized with 6-mercapto-1-hexanol (MCH). This is a well-known and commonly employed surface modification process, which involves the same principles of thiol attachment chemistry and self-assembled monolayer (SAM) formation commonly employed in the functionalization of electrodes and the formation of biosensors. Following this SAM formation, the reproducibility of the observed electrochemical signal between electrodes was seen to decrease markedly, compromising the ability to achieve consistent analytical measurements from the sensor array following this relatively simple and well-established surface modification. To successfully and consistently functionalize the sensors, it was necessary to dilute the constituent molecules by a factor of ten thousand to support adequate SAM formation on microelectrodes. The use of this multi-electrode device therefore demonstrates in a high throughput manner irreproducibility in the SAM formation process at the higher concentration, even though these electrodes are apparently functionalized simultaneously in the same film formation environment, confirming that the often seen significant electrode-to-electrode variation in label-free SAM biosensing films formed under such conditions is not likely to be due to variation in film deposition conditions, but rather kinetically controlled variation in the SAM layer formation process at these microelectrodes.

21 December 2020 in ChemRxiv
Verified
Preprint
Open access
VVVincent Vezza
Vincent Vezza
ABAdrian Butterworth
Adrian Butterworth
PLPerrine Lasserre
Perrine Lasserre
EBEwen O Blair
Ewen O Blair
AMAlexander MacDonald
Alexander MacDonald
DCDamion Corrigan
Damion Corrigan
Emerging in late 2019, the SARS-CoV-2 virus has had a devastating health and economic effects around the world forcing governments to enact restrictions on day to day life, resulting in severe economic and social disruption. The virus has stimulated new research in the fields of drug development, vaccinology and diagnostic testing. Here we present the basis for a simple, mass manufacturable saliva based electrochemical assay for the SARS-CoV-2 virus acheived through adsorption of the Angiotsnsin Converting Enzyme 2 (ACE2) into thiolated amphiphobic prefluoro monolayer assemled on a gold sensor surface. Following sensor preparation, it is possible to measure specific binding of recombinant spike protein and discriminate positive and negative samples of inactivated SARS-CoV-2 following 30 minutes incubation under ambient conditions. Representative calculations of limits of detection are made for recombinant spike protein (1.68 ng/ml) and inactivated virus (37.8 dC/mL). The assay as presented ultimately shows discrimination between positive and negative inactivated SARS-CoV-2 samples originating from clinical molecular standards kit intended for clinical and biomedical assay validation, and which is designed to mimic clinical samples through presence of cells and proteins in the sample medium. The simple design of the label free measurement and the selection of reagents involved means the assay has clear potential for transfer onto mass producible units such as screen-printed electrodes similar to glucose-format test strips, to enable widespread, low cost and rapid testing for SARS-CoV-2 in the general population

29 July 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
HRHeather Ralston
Heather Ralston
ABAdrian Butterworth
Adrian Butterworth
BCBen Clark
Ben Clark
MKMaria Katsafadou
Maria Katsafadou
VVVincent Vezza
Vincent Vezza
Damion CorriganDamion Corrigan
Damion Corrigan
Antimicrobial resistance (AMR) poses a major global health threat, often driven by empirical antibiotic use due to the relatively slow (24-72 hour) diagnostic pathway for urinary tract infections (UTIs). Due to their low cost and ease of multiplexing, electro-chemical biosensors offer a promising alternative. Herein, we report on the Microplate Dx RapidPlate™ platform, a rapid electrochemical impedance spectroscopy (EIS) based approach for accelerated antibiotic susceptibility testing (AST) directly from urine samples, without pre-treatment. This report charts the evolution of the core EIS based AST measurement from laboratory proto-type into fully realised Alpha prototype platform with an accompanying 32-channel electrochemical cartridge designed specifically for interrogation of urine samples. A total of 89 clinically derived urine samples were evaluated at three clinical sites (UK and India), with results compared against standard methods (VITEK 2 and disk diffusion). The impedance based RapidPlate™ system detected bacterial growth within 50 minutes and provided susceptibility profiles by 85 minutes, with 94% concordance to reference tests. Consistent performance is demonstrated across diverse clinical settings and organisms, including Escherichia coli and Klebsiella pneumoniae. The RapidPlate™ AST system has demonstrated great potential as a cost-effective, point-of-care tool for rapid AST, supporting and improving UTI management and antimicrobial stewardship.